Oral antisense platform · Bangkok
Written in the language of your own DNA.
immugence designs oral antisense candidates — short strands that bind a single messenger-RNA sequence, a lock cut for one key. Built from DNA information, not chemicals. Investigational, evidence-led, and engineered in Thailand.
Peer-reviewed papers
PubMed indexed
Patents granted
US + worldwide IP
US FDA orphan designations
1 granted · 1 submitted
Same team, one lineage
continuous since 2000
The science
Antisense, explained without the mystique.
The idea is old and well-understood; the hard part is making it work by mouth. Here is exactly what an immugence candidate does — and what it deliberately does not.
One sequence, one target
Each candidate is designed to complement a single messenger-RNA. Like a key cut for one lock, it binds where it should and nowhere else.
RNA-level, not gene editing
Antisense silences a signal by binding mRNA. It does not cut, rewrite, or insert anything into your genome — the DNA is left untouched.
Oral, no viral vector
Carried by a magnesium-chloride matrix and taken by mouth. No injection, no AAV, no lipid nanoparticle to clear.
Why it is gentle
Built from DNA information.
Nothing the body treats as foreign.
An antisense oligonucleotide is a short, designed strand of nucleic acid — the same alphabet your cells already read. It carries information, not a foreign chemical payload. That is the basis of its gentleness, and it is the most honest thing we can tell you about safety.
What it is
A DNA / RNA sequence
designed to match one target, taken by mouth
What it is not
- Synthetic chemicals
- Foreign proteins
- Peptides
- Live cells
- Hormones
The hard questions
“Too good to be true.”
We hear it often — so let's talk.
Skepticism is the correct response to extraordinary claims. We'd rather you bring it than walk away. Here are the four objections we hear most, answered plainly.
Antisense itself is established science — several injectable antisense drugs are already approved by major regulators. The genuinely hard problem we work on is making the chemistry stable and absorbable by mouth. We don't ask you to take that on faith: the mechanism is in the textbooks, and our specific results are in 29 peer-reviewed papers you can read.
Judge the work, not the postcode. Our research is published in international, peer-reviewed journals; our advisors hold positions at institutions such as Mahidol and a Finland Distinguished Professorship; and our laboratory and facility are registered with the Thai FDA. Credibility here is built from verifiable records, listed with their sources.
Because we are early, and we publish before we promote. immugence candidates are investigational and in research and development — we are deliberately not running consumer hype. What exists today is preclinical evidence, granted patents, and FDA orphan-drug designations in progress, each documented on its own page.
No single pill does. immugence is a platform, not a miracle product: each indication is a separate candidate with its own target, its own data, and its own honest stage of development. We make no cure claims, and nothing on this site is a registered treatment.
The receipts
A 25-year published record — the science the platform is built on.
Our founding team's oral-immunotherapy work — through Immunitor, the same corporate family — is indexed, peer-reviewed, and patented. The Mg-ASO antisense platform extends it. Every item below links to its primary source.
Open-label Phase II of oral Hepcortespenlisimut-L in 75 advanced liver-cancer patients
Phase III oral immunotherapy in tuberculosis: 68% clearance vs 23.1% placebo (152 patients)
Randomized Phase IIb in TB: 78.3% sputum conversion vs 0% placebo (p = 0.009)
Orphan-drug designation — Hepcortespenlisimut-L for hepatocellular carcinoma
Viral vaccine composition, process and methods of use — the foundation IP
Oral composition and methods for immunotherapy — metal-bound antisense delivery
In development
Twelve oral candidates. One Mg-ASO platform.
Each candidate adapts the same magnesium-stabilized antisense chemistry to a different target sequence. Stages are shown honestly — most are early; the leading programs draw on the team's published clinical evidence.
For hospitals, clinics & wellness centers
We are a platform — not a competitor.
immugence is a technology and solution provider. We don't open clinics to compete with you; we hand you the science so you become the Center of Excellence. Partners bring our antisense platform into their institution and lead in the area they choose to own.
License the platform
Technology transfer of our antisense chemistry, oral-delivery matrix, and design know-how — under a clear partnership agreement.
Build your Center of Excellence
Stand up a co-branded program in the therapeutic area you choose. Your institution leads; we provide the science underneath it.
You lead, we support
Training, supply, and scientific support from immugence. You own the patient relationship, the brand, and the clinical leadership.
Bangkok · operating nowThe first Center of Excellence
We built the first one ourselves — so you don't have to start from zero.
IMMUNIC is our own antisense clinical-research and demonstration center in Bangkok. It is the reference implementation of the model we hand to partners: proof that the platform runs in the real world, and the template your institution replicates. It is a research setting, not a retail clinic — and it is exactly what your Center of Excellence can look like.
Therapeutic areas open to partners
Candidates available to license
The people accountable
Names, degrees, and track records — on the record.
An unknown company earns trust through the people behind it. Every credential here is verifiable; we'd rather you check than assume.
Vichai Jirathitikal
Pharm. · Co-Founder & CTO
Inventor of the magnesium-stabilized oral antisense platform; principal inventor across the patent portfolio.
immugence · IMMUNIC, Bangkok
Patchalit Klinhorm
Co-Founder & CEO
Brings the platform to market and leads the Centers of Excellence program.
Founder, ECG Venture Capital
Holland Cheng
PhD · Scientific Advisor
Structural biology, cryo-EM and vaccine design; bridges to global academia.
Finland Distinguished Prof. · UC Davis · Karolinska
Pisut Pongchaikul
MD, PhD · Advisor
Medical microbiology, bioinformatics and pathogen genomics.
Asst. Prof., Mahidol University
Jonathan P. Wong
PhD · Advisor
Antisense delivery and antiviral defense; three decades at DRDC Canada.
Director, Dove Pharmaceutical Consulting
Aldar S. Bourinbaiar
MD, PhD · Co-Founder (1957–2024)
Founder of Immunitor; co-inventor of the V1/V5/V7 science and the Mongolia–Ukraine trial network.
Immunitor, USA
In the media
Reported by others — verify for yourself.
Independent press covering the founding team's work, 2011–2021. Each opens at its original source in a new tab. Distinct from the peer-reviewed evidence above.
Immunitor releases positive results of TB immunotherapy from its second clinical site
Read full articleKey Capital leads oral-pill vaccines race with Immunitor partnering and strong patenting
Read full articleKey Capital licenses Immunitor oral-pill immunotherapeutic vaccines — 23 products
Read full articleKey Capital licenses Immunitor oral-pill immunotherapeutic vaccines
Read full articleImmunitor releases positive Phase IIb TB immunotherapy results — second clinical site
Read full articleKey Capital licenses Immunitor oral-pill immunotherapeutic vaccines
Read full articleIndependent third-party coverage of the Immunitor lineage · each link opens at its original source.
Patient voices
Optional moduleHuman stories — not treatment claims.
These are personal, consented accounts from individuals who chose to take part in research. They describe people's experience, not medical results. They are not evidence of efficacy, not typical, and not a substitute for medical advice.
Before you watch
The stories behind this gate are individual experiences shared with consent. They are not medical claims, not typical results, and not a substitute for professional medical advice. immugence candidates are investigational and not registered medicines.